ARGX saw its Momentum Indicator move above the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In 61 of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at 73%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARGX's RSI Oscillator exited the oversold zone, 14 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for ARGX just turned positive on October 21, 2026. Looking at past instances where ARGX's MACD turned positive, the stock continued to rise in 34 of 49 cases over the following month. The odds of a continued upward trend are 69%.
ARGX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARGX advanced for three days, in 215 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
The Aroon Indicator entered an Uptrend today. In 180 of 262 cases where ARGX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
ARGX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is 12 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. ARGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.892) is normal, around the industry mean (3.498). P/E Ratio (33.413) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (1.189) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (12.330) is also within normal values, averaging (440.869).
IMVT moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 30 of 36 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IMVT as a result. In 77 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for IMVT just turned positive on October 22, 2026. Looking at past instances where IMVT's MACD turned positive, the stock continued to rise in 34 of 44 cases over the following month. The odds of a continued upward trend are 77%.
Following a +5.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMVT advanced for three days, in 203 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
IMVT broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IMVT entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.575) is normal, around the industry mean (3.498). P/E Ratio (-10.865) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. IMVT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 48 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ARGX | IMVT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 36 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 91 Overvalued | 31 Undervalued | |
PROFIT vs RISK RATING 1..100 | 12 | 48 | |
SMR RATING 1..100 | 41 | 98 | |
PRICE GROWTH RATING 1..100 | 40 | 41 | |
P/E GROWTH RATING 1..100 | 61 | 18 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IMVT's Valuation (31) in the null industry is somewhat better than the same rating for ARGX (91) in the Pharmaceuticals Other industry. This means that IMVT’s stock grew somewhat faster than ARGX’s over the last 12 months.
ARGX's Profit vs Risk Rating (12) in the Pharmaceuticals Other industry is somewhat better than the same rating for IMVT (48) in the null industry. This means that ARGX’s stock grew somewhat faster than IMVT’s over the last 12 months.
ARGX's SMR Rating (41) in the Pharmaceuticals Other industry is somewhat better than the same rating for IMVT (98) in the null industry. This means that ARGX’s stock grew somewhat faster than IMVT’s over the last 12 months.
ARGX's Price Growth Rating (40) in the Pharmaceuticals Other industry is in the same range as IMVT (41) in the null industry. This means that ARGX’s stock grew similarly to IMVT’s over the last 12 months.
IMVT's P/E Growth Rating (18) in the null industry is somewhat better than the same rating for ARGX (61) in the Pharmaceuticals Other industry. This means that IMVT’s stock grew somewhat faster than ARGX’s over the last 12 months.
| ARGX | IMVT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 70% | 1 day ago 87% |
| Stochastic ODDS (%) | 1 day ago 61% | 1 day ago 84% |
| Momentum ODDS (%) | 1 day ago 73% | 1 day ago 80% |
| MACD ODDS (%) | 1 day ago 69% | 1 day ago 77% |
| TrendWeek ODDS (%) | 1 day ago 69% | 1 day ago 80% |
| TrendMonth ODDS (%) | 1 day ago 67% | 1 day ago 81% |
| Advances ODDS (%) | 1 day ago 71% | 1 day ago 77% |
| Declines ODDS (%) | 11 days ago 63% | 11 days ago 81% |
| BollingerBands ODDS (%) | 1 day ago 68% | 1 day ago 89% |
| Aroon ODDS (%) | 1 day ago 69% | 1 day ago 88% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARGX’s FA Score shows that 1 FA rating(s) are green while IMVT’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARGX’s TA Score shows that 6 TA indicator(s) are bullish while IMVT’s TA Score has 4 bullish TA indicator(s).
ARGX (@Biotechnology) experienced а +4.96% price change this week, while IMVT (@Biotechnology) price change was +23.88% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
ARGX is expected to report earnings on Mar 04, 2027.
IMVT is expected to report earnings on Feb 16, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, ARGX has been loosely correlated with AXON. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGX jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To ARGX | 1D Price Change % | ||
|---|---|---|---|---|
| ARGX | 100% | +0.62% | ||
| AXON - ARGX | 40% Loosely correlated | +4.26% | ||
| ARRY - ARGX | 36% Loosely correlated | +9.94% | ||
| ONC - ARGX | 36% Loosely correlated | -0.95% | ||
| IMCR - ARGX | 36% Loosely correlated | -2.25% | ||
| IMVT - ARGX | 35% Loosely correlated | +3.72% | ||
More | ||||
A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.
| Ticker / NAME | Correlation To IMVT | 1D Price Change % | ||
|---|---|---|---|---|
| IMVT | 100% | +3.72% | ||
| ROIV - IMVT | 65% Loosely correlated | +1.60% | ||
| LXEO - IMVT | 50% Loosely correlated | +0.33% | ||
| XNCR - IMVT | 48% Loosely correlated | +1.47% | ||
| KURA - IMVT | 48% Loosely correlated | +2.11% | ||
| TSHA - IMVT | 47% Loosely correlated | +0.12% | ||
More | ||||